Introduction {#sec1}
============

Myocardial infarction (MI) represents a major health threat, which is associated with severe morbidity and mortality across the world ([@ref6]). Acute MI (AMI) may result in massive deaths of cardiomyocytes due to ischemic damage, and later formation of a fibrosis scar deprived of normal electrical conduction, and the deficient blood supply near the infarcted myocardium ([@ref25]). Adipose-derived stem cells (ADSCs) are important factors in tissue repair, presenting a potentially useful therapeutic effect in translational research on tissue regeneration ([@ref9]). ADSCs show promising effects when delivered by intracoronary and transendocardial techniques after AMI ([@ref19]). One of the major barriers for cell therapy in the treatment of MI is that the transplanted cells often fail to differentiate into myocardial cells due to the ischemia, hypoxia, and oxidative stress in the target tissue following infarction ([@ref29]). Thus, a need exists for new cellular approaches for the treatment of MI.

microRNAs (miRNAs or miRs) in blood have been highlighted as sensitive biomarkers for cardiovascular disease diagnosis, such as myocarditis and heart failure, as well as myocardial protection in cardiac surgery ([@ref27]). Reverse tissue remodeling in heart failure patients treated with cardiac resynchronization therapy is associated with favorable changes in miRNAs that regulate cardiac fibrosis, apoptosis, and hypertrophy ([@ref18]). Of note, inhibition of miR-34a, a known regulator of tumor suppression, also plays a significant role in suppressing age-associated cardiomyocyte death and fibrosis following AMI, and improves the post-injury recovery of myocardial function ([@ref2]). Furthermore, miR-34a-5p enhances cardiomyocyte apoptosis by targeting Sirt1, the NAD-dependent deacetylase sirtuin-1. Activation of the miR-34a-5p/Sirt1/p66shc pathway has a promoting effect on doxorubicin-induced cardiotoxicity, and down-regulation of the pathway could potentially contribute to the cardio-protective effect of anthracycline antibiotics ([@ref33]).

C1q/tumor necrosis factor-related protein-9 (CTRP9) is expressed in adipose tissues, wherein both primary adipocytes and stromal cells express CTRP9 transcripts ([@ref10]). Previous studies show induction by CTRP9 of vascular relaxation in mice aortic vascular rings, and link CTRP9 with potential prevention of adverse cardiovascular events ([@ref31]). Another study also demonstrated that CTRP9 systemic delivery could decrease myocardial infarct size and apoptosis after ischemia/reperfusion injury in mice, indicating a potentially protective effect on cardiomyocytes through suppression of apoptosis ([@ref11]). In addition, the adipokine CTRP9 has the potential to attenuate negative cardiac remodeling following AMI, largely by activation of a protein kinase-A (PKA)-dependent pathway ([@ref23]). Given this background, we conducted the present study to investigate the potential role of miR-34a-5p-dependent modulation of CTRP9 in the beneficial effects of ADSCs on MI.

Materials and Methods {#sec2}
=====================

Ethics Statement {#sec3}
----------------

All animal experiments were conducted with the approval of the Experimental Animal Ethics Committee of Chung Shan Medical University (No: 2198). All efforts were made to minimize animals' suffering.

Adipose-Derived Stem Cell Isolation and Culture {#sec4}
-----------------------------------------------

ADSCs were obtained from transgenic (TG) C57BL/6J mice (The Jackson Laboratory, Farmington, CT, USA) with enhanced green fluorescent protein (EGFP) ([@ref4]). In brief, the primary adipose tissue of TG mice was cleaned by washing with sterile phosphate buffered saline (PBS) containing 1% antibiotic/antifungal. The adipose cells were then enzymatically treated using 0.2% collagenase I (Invitrogen, Carlsbad, CA, USA) for 60--75 min at 37°C, filtered through a 100-μm mesh filter (Millipore, Darmstadt, Germany), and cultured in Dulbecco's modified Eagle's medium/Ham's F-12 medium (DMEM/F12, Hyclone, USA) containing fetal bovine serum (FBS) for 48 h with 5% CO~2~ at 37°C. Next, the adherent cells were cultured in DMEM/F-12 medium containing 10% FBS, 5 ng/ml basic fibroblast growth factor (bFGF, Peprotech, Rocky Hills, NJ, USA), and 1% antibiotic/antifungal. The cells were subsequently cultured at a ratio of 1:3. In accordance with the previously described method ([@ref4]), antibodies against CD105 (cat \#562759), CD90 (cat \#553005), CD45 (cat \#553081), CD31 (cat \#553373) were used to detect the surface antigens of ADSCs. Then, we undertook assessment of the multilineage potential of the ADSCs *via* adipogenesis and osteogenic differentiation. The cells at passage three in logarithmic growth phase were selected for subsequent experiments.

*In vitro* Multilineage Differentiation {#sec5}
---------------------------------------

Osteogenic differentiation was conducted. In brief, ADSCs at passage 2 were induced by 2.5 weeks of feeding (twice a week) with osteogenic induction medium consisting of 100 nM dexamethasone, 10 mM β-glycerophosphate, 0.2 mM ascorbate (all from Sigma-Aldrich Chemical Company, St Louis, MO, USA), and 10% fetal calf serum (FCS) in DMEM/F12 basal medium. Osteogenic differentiation was subsequently confirmed by mineralized matrix deposition by 0.2% alizarin red-S staining.

Adipogenic differentiation was then performed. In short, the cells were induced by 3 cycles of induction/maintenance using adipogenic induction medium consisting of 1 mM dexamethasone, 0.5 mM 3-isobutyl-1-methyl-xanthine (IBMX), 10 μg/ml recombinant human insulin, 100 mM indomethacin (all from Sigma-Aldrich Chemical Company, St Louis, MO, USA), and 10% FCS, and using adipogenic maintenance medium comprising of only 10 μg/ml recombinant human insulin and 10% FCS. After that, the induced cells were subjected to incubation for another 7 days in adipogenic maintenance medium. Adipogenic differentiation was then confirmed by the formation of neutral lipid-vacuoles stainable with 0.18% oil Red-O for 5 min (Sigma-Aldrich Chemical Company, St Louis, MO, USA). Primary normal human dermal fibroblasts served as negative control (NC). Each experiment was run in triplicate.

Dual-Luciferase Reporter Gene Assay {#sec6}
-----------------------------------

Gene fragments were artificially synthesized and introduced into the pGL3-control vector (Promega, Madison, WI, USA) using the endonuclease sites XhoI and BamH I for the establishment of a pGL3-CTRP9-wild type cell line (CTRP9-WT). The complementary sequence mutation sites of the seed sequences were then designed to construct pGL3-CTRP9-mutant type (CTRP9-MUT) vector using T4 DNA ligase. The pGL3-CTRP9-WT and pGL3-CTRP9-MUT were co-transfected with miR-34a-5p mimic respectively into 293 T cells. After 48 h, the cells were lysed. A Dual-Luciferase® Reporter Assay System assay kit (Promega, Madison, WI, USA) was used to evaluate the luciferase activity in a Luminometer TD-20/20 detector (E5311, Promega, Madison, WI, USA).

Cell Culture and Transfection {#sec7}
-----------------------------

ADSCs in logarithmic growth phase were harvested, inoculated in six-well plates at a density of 5 × 10^4^ cells/well, and cultured in complete fresh medium. When the cell density reached approximately 50--80%, the transfection was conducted using Lipofectamine 2000 (11668-027, Invitrogen, Carlsbad, CA, USA). The cells were treated with pcDNA, pcDNA-CTRP9, miR-34a-5p inhibitor blank vector, miR-34a-5p inhibitor, short hairpin RNA (shRNA) NC sequence, shRNA-CTRP9, miR-34a-5p inhibitor + shRNA-CTRP9, dimethyl sulfoxide (DMSO), U0126 \[an extracellular signal-regulated kinase 1/2 (ERK1/2) activation inhibitor, 10 μM\], miR-34a-5p inhibitor + DMSO, or miR-34a-5p inhibitor + U0126. All vectors and the miR-34a-5p inhibitor were purchased from Thermo Fisher Scientific (Waltham, MA, USA).

RNA Isolation and Quantitation {#sec8}
------------------------------

The total RNA was extracted using the miRNeasy Mini Kit (217004, Qiagen, Hilden, Germany) and reversely transcribed into complementary DNA (cDNA) with TaqMan MicroRNA Assays Reverse Transcription Primer (4427975, Applied Biosystems, Carlsbad, CA, USA). The primers were designed and synthesized by Takara (Kyoto, Japan) ([Table 1](#tab1){ref-type="table"}). RT-qPCR was performed on an ABI 7500 instrument (Applied Biosystems, Foster City, CA, USA). The expression of miR-34a-5p was examined using a TaqMan microRNA assay kit (Applied Biosystems, Carlsbad, CA, USA) ([@ref14]). U6 was taken as the internal reference of miR-34a-5p and β-actin was the reference for other genes. The fold changes in expression were calculated by means of relative quantification 2^−ΔΔCt^.

###### 

Primer sequences for RT-qPCR.

  Genes                               Primer sequences (5′-3′)
  ----------------------------------- ----------------------------------
  miR-34a-5p                          F: 5′-GGGGTGGCAGTGTCTTAGC-3′
  R: 5′-GTGCGTGTCGTGGAGTCG-3′         
  CTRP9                               F: 5′-CCCCTTGTGCCCAAGAGTGCTTT-3′
  R: 5′-CTCTCTCCTCCTGTCACCTGCAT-3′    
  ERK1                                F: 5′-GCGTTACATGTGGCAGCTTGA-3′
  R: 5′-TGGAACCCCACCCCATTTT-3′        
  MMP-9                               F: 5′-TGCGACCACATCGAACTTCG-3′
  R: 5′-CCAGAGAAGAAGAAAACCCTCTTG-3′   
  NRF2                                F: 5′-CTCGCTGGAAAAAGAAGTGG-3′
  R: 5′-CCGTCCAGGAGTTCAGAGAG-3′       
  MnSOD                               F: 5′-ATGTTGTGGGAGTCCAA-3′
  R: 5′-TGAAGGTAGTAAGCGTGCTC-3′       
  HO-1                                F: 5′-ACTTTCAGAAGGGTCAGGTGTCC-3′
  R: 5′-TTGAGCAGGAAGGCGGTCTTAG-3′     
  BNP                                 F: 5′-TCCATCAGAGGGGTCACAC-3′
  R: 5′-GCCTTGTGAAGGGGTGATTA-3′       
  ANP                                 F: 5′-CACAGATCTGATGGATTTCAAGA-3′
  R: 5′-CCTCATCTTCTACCGGCATC-3′       
  U6                                  F: 5′-GCATGACGTCTGCTTTGGA-3′
  R: 5′-CCACAATCATTCTGCCATCA-3′       
  β-actin                             F: 5′-GACATGGAGAAGATCTGGCA-3′
  R: 5′-GGTCTTTACGGATGTCAACG-3′       

*RT-qPCR, Reverse transcription quantitative polymerase chain reaction; CTRP9, C1q/tumor necrosis factor-related protein-9; ERK1, Extracellular signal-regulated kinase 1; MMP-9, Matrix metalloproteinase-9; NRF2, Nuclear factor (erythroid-derived 2)-like 2; MnSOD, Manganese superoxide dismutase; HO-1, Heme oxygenase-1; BNP, Brain natriuretic peptide; ANP, Atrial natriuretic peptide*.

Western Blot Analysis {#sec9}
---------------------

The total protein in tissues or cell lines was extracted using lysis buffer (C0481, Sigma, St Louis, MO, USA), with the protein concentration determined using a bicinchoninic acid assay kit (23225, Pierce, Rockford, IL, USA). Following separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 50 μg of protein was transferred onto polyvinylidene fluoride membranes (ISEQ00010, Millipore, Billerica, MA, USA) using the wet transfer method. The membranes were then blocked with Tris-buffered saline Tween-20 (TBST) containing 5% skimmed milk for 2 h and incubated overnight at 4°C with primary rabbit monoclonal antibodies to mouse CTRP9 (1:1,000, NBP2--46834), ERK1, (1:1,000, ab32537), matrix metalloproteinase-9 (MMP-9) (1:1,000, ab38898), nuclear factor (erythroid-derived 2)-like 2 (NRF2) (1:1,000, ab137550), manganese superoxide dismutase (MnSOD) (1:5,000, ab13533), heme oxygenase-1 (HO-1) (1:1,000, ab13248), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:2,500, ab9485). All primary antibodies were from Abcam Inc. (Cambridge, MA, USA), except CTRP9, which was from Novus Biologicals (CO, USA). The membrane was exposed to secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) (1:2,000, ab6721, Abcam Inc., Cambridge, MA, USA) for 1 h of incubation, followed by development with an enhanced chemiluminescence (ECL) reagent in the dark. The band intensities were quantified using the Image J software. The ratio of the gray value of the target band to GAPDH was representative of the relative protein expression.

5-Ethynyl-2′-Deoxyuridine Assay {#sec10}
-------------------------------

The proliferation of ADSCs was measured according to the instructions of the Click-iT EdU Alexa Fluor 647 Imaging Kit (C10340, Invitrogen, Carlsbad, CA, USA). In brief, the ADSCs in the logarithmic phase of growth were collected and seeded into laser confocal dishes with the concentration adjusted to 1 × 10^5^ per dish, followed by overnight incubation at 37°C with 5% CO~2~. The following day, the culture medium was replaced with the treatment medium and placed in an incubator for 48 h of reaction. The culture medium replenished with fresh medium along with the 5-ethynyl-2′-deoxyuridine (EdU) staining solution and incubated for 6 h. The cells were washed twice using 1 ml of 3% bovine serum albumin (BSA) in PBS (5 min/time), fixed by addition of 1 ml of 3.7% paraformaldehyde for 15 min, washed twice again with 1 ml of 3% BSA in PBS, and then incubated at ambient temperature with 1 ml 0.5% Triton X-100 for 20 min. Finally, the cells were washed twice using 1 ml of 3% BSA in PBS, mixed with 0.5 ml of Click-iT® reaction cocktail, and then incubated at ambient temperature for 30 min in subdued light. An additional two washes with 1 ml of 3% BSA in PBS were carried out, followed by 30-min incubation with Hoechst3334. A total of 6--10 visual fields were randomly selected, observed, and photographed under a fluorescence microscope (Nikon, Japan). EdU-positive rate (%) was defined as the number of positive cells divided by the total of positive and negative cells, multiplied by 100%.

Scratch Test {#sec11}
------------

After 30 min of ultraviolet irradiation, the cells were inoculated into a cell culture plate. When the cell confluence reached approximately 90%, the cells were scratched linearly using a 20-μl plastic pipette tip, followed by culture with 1% low FBS culture medium. The initial scratch image was photographed under an inverted microscope view to be used as a reference (0 h). The distance between the cells on both sides of the scratch was taken as the initial distance. The cells were observed and photographed at the same position at various time points over the next 24 h, and the relative migration distance of cells in each group was calculated relative to the initial position.

Transwell Assay {#sec12}
---------------

The serum containing ADSCs was starved for 12--24 h, digested, and re-suspended in 0.2% serum-free BSA in PBS, with cell concentration adjusted to 1 × 10^6^ cells/μl. A total of 200 μl of cell suspension was added to the apical chamber of pre-cooled Transwell chamber coated with Matrigel gel and 600 μl of conditional medium containing 10% FBS was added to the basolateral chamber. Following 24 h of culture, the cells were fixed by 10% paraformaldehyde for 20 min, and stained for 15 min using 0.1% crystal violet. The cells in the apical chamber and matrix glue were wiped off using a cotton swab. Under a light microscope (200 ×), the number of penetrating cells in five visual fields in each membrane was counted and recorded.

Flow Cytometry {#sec13}
--------------

Immunophenotype identification was initially carried out. In short, ADSCs at passage 2 were detached with 0.05% trypsin/0.02% ethylenediaminetetraacetic acid (EDTA) (Invitrogen, Carlsbad, CA, USA), and fixed in ice-cold 1% paraformaldehyde for 30 min. Cell aliquots (1.0 × 10^6^) were then washed in flow cytometry buffer (FCB) supplemented with 2% FBS and 0.2% Tween-20 in PBS, followed by 30 min of incubation at 4°C with FCB containing fluorescein phycoerythrin (PE)-conjugated rat antibodies against mouse: CD105 (cat\#562759), CD90 (cat\#553005), CD45 (cat\#553081), CD31 (cat\#553373) (all diluted at 1:250; all from BD Pharmigen, San Diego, CA, USA). The cells were stained with isotype-identical nonspecific IgG (BD Pharmingen, San Diego, CA, USA) as control to assess background fluorescence. The stained cells, excluding dead ones, were subsequently analyzed using FACScan argon laser cytometer (BD Biosciences, San Diego, CA, USA). FlowJo 5.7 software (Tree Star Inc., San Carlos, CA, USA) was used for the following data analyses.

Subsequently, cell cycle and apoptosis of ADSCs were detected. Briefly, after 48 h of transfection, the ADSCs were collected and detached with 0.25% trypsin with the concentration adjusted to 1 × 10^6^ cells/ml. Following centrifugation, the cells were re-suspended in 70% pre-cooled ethanol and fixed at 4°C overnight. Subsequently, a 100-μl portion of suspension was collected and mixed with 1 ml 50 mg/ml propidium iodide (PI) solution (containing RNAase) in the dark for 30 min, and then filtered with a 300-mesh nylon. Then the cell cycle was analyzed using a flow cytometer (BD Bioscience, Franklin Lakes, NJ, USA) and fluorescence was viewed with excitation wavelength at 488 nm. The rate of apoptotic cells was detected by staining with Annexin V-phycoerythrin (PE)/7-aminoactinomycin D (7-AAD) (BD, Pharmingen, CA, USA) according to the manufacturer's instructions. Briefly, the cells were suspended in 200μl of binding buffer and then incubated with 10μl of PE-Annexin V solution and 10μl of 7-AAD at room temperature for 30min, respectively. A FACScan flow cytometry (BD, Immunocytometry Systems, San Jose, CA, USA) was used for fluorescence intensity measurement, which was then analyzed by the FACScan software.

Animal Experiments {#sec14}
------------------

A total of 60 healthy male C57BL/6J mice, weighing 25--30 g, were provided by our experimental animal center. The mice were acclimatized in the specific pathogen-free (SPF) laboratory at 22--25°C with 60--65% humidity for 7 days, and given *ad libitum* access to food and water. The animal model of MI was established as previously reported ([@ref13]). In brief, the mice were anesthetized with isoflurane. The anterior descending branch of the left coronary artery was ligated at 2--3 mm below the pulmonary artery using the 6--0 round needle thread to create the ischemia injury. About 3--5 mm of the loop was reserved outside the thoracic cavity. After 5 min of ligation, injections of pharmaceuticals were made through the caudal vein. The mice were randomly divided into six groups: sham group (intracardial injection of normal saline), MI group, MI + ADSC group (intracardial injection of ADSCs), MI + miR-34a-5p antagomir + ADSC group (intracardial injection of ADSCs transfected with miR-34a-5p antagomir), MI + miR-34a-5p antagomir + shRNA-CTRP9 + ADSC group (intracardial injection of ADSCs transfected with miR-34a-5p antagomir and shRNA-CTRP9), MI + shRNA-CTRP9 + ADSC group (intracardial injection of ADSCs transfected with shRNA-CTRP9), with 10 mice in each group. Subgroups of five mice each were subjected to a hemodynamic study and echocardiography at 12 h or the fourth week after MI modeling. Then, the mice were euthanized and the myocardial tissues were extracted for terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining and Masson's trichrome staining.

Echocardiography {#sec15}
----------------

At 12 h or the fourth week after MI modeling, as previously described ([@ref7]), the M-mode images of mice anesthetized with 3% sodium pentobarbital were obtained using the Visualsonics 770 echocardiography system (VisualSonics, Toronto, Canada). The heart was observed in the short-axis between two papillary muscles. Each measurement was obtained by means of M mode, based on the results of an average of three consecutive heartbeats. Next, left ventricular internal dimensions (LVID) at diastole and systole (LVIDd and LVIDs) were calculated. In addition, left ventricular ejection fraction (LVEF) was calculated in an automatic manner by the echocardiography software based on the following formula: LVEF (%) = 100 × \[(LVIDd^3^ − LVIDs)^3^/LVIDd^3^\].

Hemodynamic Study {#sec16}
-----------------

A Millar tip-pressure catheter was used to evaluate cardiac hemodynamic function *in vivo* at 12 h or the fourth week following MI. The mice were anesthetized by 3% sodium pentobarbital, and the right common carotid artery was then surgically isolated and cannulated using a 1.4 French micromanometer (Millar Instruments, Houston, Texas, USA). *Via* catheter advancement into the left ventricular (LV) cavity, LV pressure, LV end-diastolic pressure (LVEDP), and heart rate (HR) were assayed, and data were collected and analyzed using a PowerLab System (Milford, MA, USA). Finally, we recorded maximal values of the instantaneous first derivative of LV pressure, i.e., +dP/dtmax, a measure of cardiac contractility.

TUNEL Staining {#sec17}
--------------

At the fourth week after MI modeling, the apoptosis of myocardial tissues of mice in each group was measured using TUNEL staining as per the instructions of the Roche *in situ* cell apoptosis detection kits (11767305001 and 11767291910, Sigma, St Louis, MO, USA). Under a laser confocal microscope (Nikon, Japan), the nucleus was stained blue with 4′,6-diamidino-2-phenylindole (DAPI) and the apoptotic positive cells were stained green. Then apoptotic cells were counted in five randomly selected high-power visual fields in each group of mice using the Pro-Plus Motic Med 6.0 software (Motic Incorporation, USA). The apoptosis rate was defined as the number of apoptotic cells/the total number of cells × 100%.

Masson's Trichrome Staining {#sec18}
---------------------------

At the fourth week after MI modeling, the myocardial tissues of mice in each group were fixed for 16--18 h using 4% paraformaldehyde solution, hydrated, embedded into paraffin, sectioned at a thickness of 10 μm, and washed with running water and distilled water for 3 min respectively. Then, the cells were stained using Weigert hematoxylin for 5 min (1.15973, Sigma, St Louis, MO, USA), stained with Masson ponceau acid fuchsin solution for 5 min, soaked with 2% glacial acetic acid for 30 s, differentiated with phosphomolybdic acid solution, and stained with aniline blue or light green solution for 5 min. Subsequently, the tissue sections were soaked in 2% glacial acetic acid for 15 s, dehydrated, cleared and fixed with neutral balsam, followed by cover-slipping and observation under an optical microscope (DSX100, Olympus, Tokyo, Japan). The collagen-rich deformed infarct area was stained blue and the cell matrix was stained red. Five visual fields were randomly selected from each section and then analyzed using the ImageJ software. The degree of myocardial fibrosis was expressed as the percentage of fibrotic area in the total area.

Statistical Analysis {#sec19}
--------------------

Data statistical analyses were analyzed using SPSS 21.0 (IBM Corp, Armonk, NY, USA). Measurement data were expressed as mean ± standard deviation (s.d.). Data following a normal distribution and with homogeneity of variance between two groups were compared using the unpaired *t*-test. Comparisons among multiple groups were analyzed by one-way analysis of variance (ANOVA), followed by Tukey's *post hoc* test. *p* \< 0.05 was taken to be statistically significant.

Results {#sec20}
=======

miR-34a-5p Targets C1q/Tumor Necrosis Factor-Related Protein-9 and Inhibits Its Expression {#sec21}
------------------------------------------------------------------------------------------

An online website[^1^](#fn001){ref-type="fn"} was used to investigate the upstream regulation mechanism of CTRP9 in the process of stem cell transplantation in MI tissues. A specific binding region existing between 3′untranslated region (3′UTR) of CTRP9 and miR-34a-5p revealed that CTRP9 was a target gene of miR-34a-5p ([Figure 1A](#fig1){ref-type="fig"}). Dual-luciferase reporter gene assay ([Figure 1B](#fig1){ref-type="fig"}) showed that luciferase activity of 3′UTR in CTRP9 WT was inhibited by the miR-34a-5p mimic (*p* \< 0.05), while no obvious change was observed in the luciferase activity of 3′UTR in CTRP9 MUT (*p* \> 0.05), indicating that miR-34a-5p could indeed target CTRP9. In order to study whether miR-34a-5p could affect CTRP9 expression in ADSCs, we first isolated the ADSCs from TG C57BL/6J mice with EGFP. We then performed flow cytometry to analyze the molecular markers of ADSCs, which showed that ADSCs were CD105-positive, CD90-positive, CD45-negative, and CD31-negative ([Supplementary Figure S1A](#SM1){ref-type="supplementary-material"}). Subsequent results under an optical microscopy revealed that ADSCs exhibited unique fibroblast morphology *in vitro*, such as spindle-shaped monocytes ([Supplementary Figure S1B](#SM1){ref-type="supplementary-material"}). The results obtained by fluorescence microscopy showed that ADSCs were all EGFP-positive cells ([Supplementary Figure S1C](#SM1){ref-type="supplementary-material"}). Oil red O staining illustrated that ADSCs had adipogenic differentiation ability ([Supplementary Figure S1D](#SM1){ref-type="supplementary-material"}) and alizarin red staining demonstrated that ADSCs had osteogenic differentiation ability ([Supplementary Figure S1E](#SM1){ref-type="supplementary-material"}). These results were indicative of successful characterization of ADSCs and suggested that ADSCs possessed "stemness" properties. Western blot analysis ([Figure 1C](#fig1){ref-type="fig"}) showed that CTRP9 expression was up-regulated in ADSCs treated with the miR-34a-5p inhibitor (*p* \< 0.05). These findings confirmed that CTRP9 is a target gene of miR-34a-5p.

![CTRP9 is a target gene of miR-34a-5p. **(A)** Predicted binding sites between miR-34a-5p and 3′UTR of CTRP9. **(B)** Luciferase activity detected using the dual-luciferase reporter gene assay. ^\*^*p* \< 0.05 vs. the mimic-NC group. **(C)** The effect of miR-34A-5p inhibitor on CTRP9 expression detected by western blot analysis. ^\#^*p* \< 0.05 vs. the miR-34a-5p inhibitor-NC group. Data (mean ± s.d.) between two groups were analyzed by the unpaired *t*-test. The experiment was repeated three times. CTRP9, C1q/tumor necrosis factor-related protein-9; miR-34a-5p, microRNA-34a-5p; WT, wild type; MUT, mutant type; 3′UTR, 3′ untranslated region; NC, negative control; s.d., standard deviation.](fphys-10-01445-g001){#fig1}

Down-Regulated miR-34a-5p Promotes Downstream Pathway-Related Gene Expression {#sec22}
-----------------------------------------------------------------------------

RT-qPCR and western blot analysis were conducted to detect the expression of ERK1, MMP-9, NRF2, and antioxidant proteins (MnSOD, HO-1 and Prdx1). As shown in [Figure 2](#fig2){ref-type="fig"}, compared with the cells not transfected with any sequence, there was no significant change in the expression of ERK1, MMP-9, NRF2, MnSOD, HO-1, and Prdx1 in cells treated with blank vector, sh-NC, miR-34a-5p inhibitor NC, or DMSO (*p* \> 0.05). Compared with cells treated with sh-NC, there was reduced expression of ERK1, MMP-9, NRF2, MnSOD, and HO-1 in cells treated with shRNA-CTRP9 (*p* \< 0.05). Similar trends were observed in cells treated with U0126 when compared with cells treated with DMSO, or in cells treated with miR-34a-5p inhibitor + shRNA-CTRP9 in comparison with cells treated with miR-34a-5p inhibitor (*p* \< 0.05). The expression of ERK1, MMP-9, NRF2, MnSOD, and HO-1 was all increased in the cells treated with miR-34a-5p inhibitor, but this increase was blocked by miR-34a-5p inhibitor + shRNA-CTRP9 (*p* \< 0.05). In comparison to cells receiving miR-34a-5p inhibitor + DMSO treatment, there was a decline in the aforementioned factors in the cells treated with miR-34a-5p inhibitor + U0126 (*p* \< 0.05). Therefore, down-regulation of miR-34a-5p potentiated the expression of the downstream pathway-related genes through CTRP9 up-regulation.

![Down-regulation of miR-34a-5p promotes CTRP9 expression. **(A)** The expression of ERK1, MMP-9, NRF2, MnSOD, and HO-1 in ADSCs detected by RT-qPCR. **(B,C)** Western blot analysis of ERK1, MMP-9, NRF2, MnSOD, and HO-1 proteins in ADSCs. ^\*^*p* \< 0.05 vs. the vector group; ^\#^*p* \< 0.05 vs. the sh-NC group; ^&^*p* \< 0.05 vs. the miR-34a-5p inhibitor NC group; ^@^*p* \< 0.05 vs. the miR-34a-5p inhibitor group; ^\$^*p* \< 0.05 vs. the DMSO group; ^%^*p* \< 0.05 vs. the miR-34a-5p inhibitor + DMSO group; Data (mean ± s.d.) among multiple groups were analyzed by one-way ANOVA, followed by Tukey's *post hoc* test. Log-rank was used for univariate analysis. The experiment was repeated three times. CTRP9, C1q/tumor necrosis factor-related protein-9; miR-34a-5p, microRNA-34a-5p; ERK1, extracellular signal-regulated kinase 1; MMP-9, matrix metalloproteinase-9; NRF2, nuclear factor (erythroid-derived 2)-like 2; MnSOD, manganese superoxide dismutase; HO-1, heme oxygenase-1; RT-qPCR, reverse transcription quantitative polymerase chain reaction; ADSCs, adipose-derived stem cells; sh, short hairpin; NC, negative control; DMSO, dimethyl sulfoxide; s.d., standard deviation; ANOVA, analysis of variance.](fphys-10-01445-g002){#fig2}

Down-Regulated miR-34a-5p Promotes Adipose-Derived Stem Cell Proliferation *in vitro* by Up-Regulating C1q/Tumor Necrosis Factor-Related Protein-9 Expression {#sec23}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

EdU assay was employed to examine the proliferation of ADSCs. As shown in [Figures 3A](#fig3){ref-type="fig"},[B](#fig3){ref-type="fig"}, the proliferation of cells treated with pcDNA-CTRP9 was accelerated than that upon pcDNA treatment (*p* \< 0.05). Compared with the cells treated with sh-NC, the proliferation speed was lower in the cells treated with shRNA-CTRP9 (*p* \< 0.05), whereas compared with the cells treated with DMSO, the proliferation speed was reduced in the cells treated with U0126 (*p* \< 0.05). In contrast to the cells following miR-34a-5p inhibitor NC transfection, the cell proliferation was elevated in the cells treated with miR-34a-5p inhibitor + shRNA-CTRP9 (*p* \< 0.05). Relative to the cells treated with miR-34a-5p inhibitor, the cell proliferation was slowed down in the cells transfected with miR-34a-5p inhibitor + U0126 (*p* \< 0.05). Compared with miR-34a-5p inhibitor + DMSO treatment, the proliferation speed was lower upon treatment with miR-34a-5p inhibitor + U0126 (*p* \< 0.05). To sum up, down-regulation of miR-34a-5p *in vitro* promoted ADSC proliferation by up-regulating CTRP9 and the ERK1/2 pathway.

![Down-regulation of miR-34a-5p promotes ADSC proliferation by up-regulation of CTRP9 *in vitro*. **(A,B)** ADSC proliferation in each group measured by EdU assay (blue represents Hoechst-positive cells and red represents EdU-positive cells) (200 ×). ^\*^*p* \< 0.05 vs. the vector group; ^\#^*p* \< 0.05 vs. the sh-NC group; ^&^*p* \< 0.05 vs. the miR-34a-5p inhibitor NC group; ^@^*p* \< 0.05 vs. the miR-34a-5p inhibitor group; ^\$^*p* \< 0.05 vs. the DMSO group; ^%^*p* \< 0.05 vs. the miR-34a-5p inhibitor + DMSO group. Data (mean ± s.d.) among multiple groups were analyzed by one-way ANOVA, followed by Tukey's *post hoc* test. Log-rank was used for univariate analysis. The experiment was repeated three times. CTRP9, C1q/tumor necrosis factor-related protein-9; miR-34a-5p, microRNA-34a-5p; ADSC, adipose-derived stem cell; sh, short hairpin; NC, negative control; EdU, 5-ethynyl-2′-deoxyuridine; DMSO, dimethyl sulfoxide; s.d., standard deviation; ANOVA, analysis of variance.](fphys-10-01445-g003){#fig3}

Down-Regulated miR-34a-5p Promotes Adipose-Derived Stem Cell Migration *in vitro* by Up-Regulating C1q/Tumor Necrosis Factor-Related Protein-9 Expression {#sec24}
---------------------------------------------------------------------------------------------------------------------------------------------------------

Scratch test and Transwell assay were adopted to evaluate the effects of miR-34a-5p and CTRP9 on the migration of ADSC ([Figure 4](#fig4){ref-type="fig"}). Compared with the cells treated with sh-NC, cell migration distance and number of migrated cells were lower upon treatment with shRNA-CTRP9 (*p* \< 0.05). Compared with DMSO-treated cells, the cell migration distance and number of migrated cells were also reduced in the cells treated with U0126 (*p* \< 0.05). Exposure to miR-34a-5p inhibitor elevated cell migration distance and number of migrated cells, while shRNA-CTRP9 reversed these effects of miR-34a-5p inhibitor (*p* \< 0.05). Furthermore, U0126 reversed the effects of miR-34a-5p inhibitor more than DMSO treatment did (*p* \< 0.05). Together, these results showed that down-regulation of miR-34a-5p *in vitro* stimulated ADSC proliferation by up-regulating CTRP9 and the ERK1/2 pathway.

![Inhibition of miR-34a-5p promotes ADSC migration *in vitro* by up-regulating CTRP9. **(A,B)** Cell migration after transfection detected by the scratch test. **(C,D)** Cell migration after transfection detected by Transwell assay (200 ×). ^\*^*p* \< 0.05 vs. the vector group; ^\#^*p* \< 0.05 vs. the sh-NC group; ^&^*p* \< 0.05 vs. the miR-34a-5p inhibitor NC group; ^@^*p* \< 0.05 vs. the miR-34a-5p inhibitor group; ^\$^*p* \< 0.05 vs. the DMSO group; ^%^*p* \< 0.05 vs. the miR-34a-5p inhibitor + DMSO group. Data (mean ± s.d.) among multiple groups were analyzed by one-way ANOVA, followed by Tukey's *post hoc* test. Log-rank was used for univariate analysis. The experiment was repeated three times. CTRP9, C1q/tumor necrosis factor-related protein-9; miR-34a-5p, microRNA-34a-5p; ADSC, adipose-derived stem cell; sh, short hairpin; NC, negative control; DMSO, dimethyl sulfoxide; s.d., standard deviation; ANOVA, analysis of variance.](fphys-10-01445-g004){#fig4}

Down-Regulated miR-34a-5p Suppresses Adipose-Derived Stem Cell Apoptosis *in vitro* by Up-Regulating C1q/Tumor Necrosis Factor-Related Protein-9 Expression {#sec25}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Cell cycle of ADSC was detected by PI staining, and the cell apoptosis was examined by Annexin V-PE/7-ADD staining. As shown in [Figures 5A](#fig5){ref-type="fig"}--[D](#fig5){ref-type="fig"}, compared with the cells that were not transfected with any sequence, no obvious changes were detected in cell cycle and apoptosis in the cells treated with blank vector, sh-NC, miR-34a-5p inhibitor NC, or DMSO (*p* \> 0.05). Compared with the cells treated with blank vector, there were fewer G1 phase-arrested cells yet more S phase-arrested cells in addition to decreased apoptosis rate in the cells treated with pcDNA-CTRP9 (*p* \< 0.05). Treatment with shRNA-CTRP9 resulted in more G1 phase-arrested cells but fewer S phase-arrested cells together with an increased apoptosis rate (*p* \< 0.05). Compared with the cells transfected with DMSO, there were more G1 phase-arrested cells while fewer S phase-arrested cells along with increased apoptosis rate in the cells treated with U0126 (*p* \< 0.05). Transfection with miR-34a-5p inhibitor resulted in fewer G1 phase-arrested cells yet more S phase-arrested cells as well as diminished apoptosis rate (*p* \< 0.05). However, compared with cells treated with miR-34a-5p inhibitor, the abundance of G1 phase-arrested cells increased, while S phase-arrested cell numbers decreased and the apoptosis rate was elevated in cells treated with miR-34a-5p inhibitor (*p* \< 0.05). In comparison to the cells treated with miR-34a-5p inhibitor + DMSO, miR-34a-5p inhibitor + U0126 treatment resulted in more G1 phase-arrested cells, fewer S phase-arrested cells, and increased apoptosis rate (*p* \< 0.05). The results demonstrate that the inhibition of miR-34a-5p reduces the cell apoptosis by promoting CTRP9 expression.

![Inhibition of miR-34a-5p suppresses ADSC apoptosis *in vitro* by the promotion of CTRP9 expression. **(A,B)** Distribution of ADSC cycles measured using flow cytometry. **(C,D)** ADSC apoptosis measured using Annexin V-PE/7-ADD staining with flow cytometry. ^\*^*p* \< 0.05 vs. the vector group; ^\#^*p* \< 0.05 vs. the sh-NC group; ^&^*p* \< 0.05 vs. the miR-34a-5p inhibitor NC group; ^@^*p* \< 0.05 vs. the miR-34a-5p inhibitor group; ^\$^*p* \< 0.05 vs. the DMSO group; ^%^*p* \< 0.05 vs. the miR-34a-5p inhibitor + DMSO group. Data (mean ± s.d.) among multiple groups were analyzed by one-way ANOVA, followed by Tukey's *post hoc* test. The experiment was repeated three times. CTRP9, C1q/tumor necrosis factor-related protein-9; miR-34a-5p, microRNA-34a-5p; ADSC, adipose-derived stem cell; sh, short hairpin; NC, negative control; DMSO, dimethyl sulfoxide; s.d., standard deviation; ANOVA, analysis of variance.](fphys-10-01445-g005){#fig5}

Down-Regulated miR-34a-5p Promotes the Protective Role of Adipose-Derived Stem Cells Against Myocardial Infarction *in vivo* by Up-Regulating Adipose-Derived Stem Cell Expression {#sec26}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Finally, to explore whether miR-34a-5p/CTRP9 could modulate the protective effect of ADSC transplantation against MI damage in mice, we monitored the cardiac functions of mice in each group. As shown in [Table 2](#tab2){ref-type="table"}, we first tested the echocardiograms and hemodynamic parameters of mice, the results of which were indicative of successful establishment of the mouse MI model. Next, we performed flow cytometry to measure myocardial cell apoptosis in mice of each group. Compared with the sham-operated mice, the MI mice showed reduced LVEF and + dp/dtmax, in addition to notably increased rates of LVEDP and TUNEL-positive cells; the same trend was detected in the MI mice transplanted with ADSCs with additional miR-34a-5p antagomir + shRNA-CTRP9 treatment in comparison to the MI mice transplanted with ADSCs with only miR-34a-5p antagomir treatment (*p* \< 0.05) ([Figures 6A](#fig6){ref-type="fig"}--[D](#fig6){ref-type="fig"}). Compared with MI mice transplanted with ADSCs alone, the MI mice also treated with miR-34a-5p antagomir presented with increased LVEF and + dp/dtmax, in addition to notably decreased LVEDP and TUNEL-positive rate (*p* \< 0.05) ([Figures 6A](#fig6){ref-type="fig"}--[D](#fig6){ref-type="fig"}). Masson's trichrome staining showed that compared with the sham group, the structure of myocardial cells in the untreated MI group, was replaced with an irregular and disordered arrangement of cells. We also saw increased myocardial cell numbers and decreased number of myocardial fibers in myocardial tissue of the MI mice transplanted with ADSCs alone, and with ADSCs in conjunction with treatment with miR-34a-5p antagomir. Compared with the MI mice transplanted with ADSCs along with miR-34a-5p antagomir treatment, the MI mice transplanted with ADSCs with additional miR-34a-5p antagomir + shRNA-CTRP9 treatment showed more surviving myocardial fibers (*p* \< 0.05) ([Figure 6E](#fig6){ref-type="fig"}). Subsequent results from RT-qPCR revealed increased expression of miR-34a, brain natriuretic peptide (BNP), and atrial natriuretic peptide (ANP) in myocardial tissues in MI mice as compared with concentrations in sham-operated mice (*p* \< 0.05). Compared with untreated MI mice, expression of miR-34a, BNP, and ANP in myocardial tissues in MI mice treated with ADSC or miR-34a-5p antagomir + ADSC presented was markedly reduced (*p* \< 0.05). In comparison with mice treated with shRNA-CTRP9 + ADSC, expression of miR-34a, BNP, and ANP was decreased in myocardial tissues upon shRNA-CTRP9 + ADSC treatment (*p* \< 0.05) ([Figure 6F](#fig6){ref-type="fig"}). These results demonstrate that down-regulation of miR-34a-5p or up-regulation of CTRP9 promotes the protective role of ADSCs against MI damage.

###### 

Echocardiography results of the study groups.

  Group               Units   Sham           MI 12 h
  ------------------- ------- -------------- -------------------------------------------------
  Ejection fraction   \%      61.54 ± 1.25   17.26 ± 3.18[^\*^](#tfn1){ref-type="table-fn"}
  Stroke volume       μl      52.32 ± 4.87   20.59 ± 3.71[^\*^](#tfn1){ref-type="table-fn"}
  LVID;s              mm      2.84 ± 0.35    4.75 ± 0.33[^\*^](#tfn1){ref-type="table-fn"}
  LVID;d              mm      4.51 ± 0.58    4.87 ± 0.29
  Volume;s            μl      35.67 ± 3.88   92.08 ± 8.65[^\*^](#tfn1){ref-type="table-fn"}
  Volume;d            μl      93.15 ± 8.74   120.64 ± 9.13[^\*^](#tfn1){ref-type="table-fn"}
  LVAW;s              mm      1.46 ± 0.28    1.28 ± 0.19
  LVAW;d              mm      1.11 ± 0.17    1.05 ± 0.12
  LVPW;s              mm      1.41 ± 0.19    1.20 ± 0.27
  LVPW;d              mm      1.06 ± 0.11    0.98 ± 0.16

*N = 10*,

p \< 0.05

*vs. the sham group. Data (mean ± s.e.) among multiple groups were analyzed by unpaired *t*-test. MI, Myocardial infarction; LVID;s, Left ventricular internal diameter;systole. LVID;d, Left ventricular internal diameter;diastole. Volume;s, Left ventricle volume systole. Volume;d, Left ventricle volume diastole. LVAW;s, Left ventricular anterior wall (systole). LVAW;d, Left ventricular anterior wall (diastole). LVPW;s, Left ventricular posterior wall (systole). LVPW;d, Left ventricular posterior wall (diastole)*.

![Down-regulated miR-34a-5p promotes the protective role of ADSCs against MI damage *in vivo* by up-regulating CTRP9 expression. **(A)** LVEF of mice in each group. **(B)** +dp/dtmax of mice in each group. **(C)** LVEDP of mice in each group. **(D)** Myocardial cell apoptosis in mice of each group detected by TUNEL staining (400 ×). **(E)** Masson' s trichrome staining of myocardial tissues in mice of each group (400 ×). **(F)** Expression of miR-34a, BNP, and ANP in myocardial tissues detected using RT-qPCR. ^\*^*p* \< 0.05 vs. the sham group; ^\#^*p* \< 0.05 vs. the MI + ADSC group; ^&^*p* \< 0.05 vs. the MI + miR-34a-5p antagomir + ADSC group. Data (mean ± s.d.) among multiple groups were analyzed by one-way ANOVA, followed by Tukey's *post hoc* test. The experiment was repeated three times. CTRP9, C1q/tumor necrosis factor-related protein-9; miR-34a-5p, microRNA-34a-5p; ADSC, adipose-derived stem cell; MI, myocardial infarction; LVEF, left ventricular ejection fraction; LVEDP, left ventricular end-diastolic pressure; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling; s.d., standard deviation; ANOVA, analysis of variance.](fphys-10-01445-g006){#fig6}

Discussion {#sec27}
==========

MI, a major public health threat to people worldwide, can result in fibrotic scar formation and left ventricular remodeling, including cardiac dilatation, contractile dysfunction, and cardiomyocyte hypertrophy ([@ref6]). Infusion with an ADSC-conditioned medium has been reported to improve the function of infarcted hearts, with a large therapeutic effect of ADSC transplantation attributable to paracrine-mediated cardio-protection and angiogenesis ([@ref32]). In addition, plasma miRNAs were found to be dysregulated in AMI, which potentially gives a new index of disease mechanisms of acute coronary syndromes (ACSs) in individual patients ([@ref24]). CTRP9 was suggested to possess a protective function against acute myocardial injury ([@ref12]). The results of the current study indicate that inhibition of miR-34a-5p can initiate up-regulation of CTRP9, thus promoting the protective effects of ADSCs against MI in this mouse model.

We found that down-regulation of miR-34a-5p was able to inhibit MI damage, and that there was elevated miR-34a-5p expression in MI cells and tissues. Recent evidence has proposed the crucial functional roles of miRNAs in cardiac diseases due to their involvement in cardiac resynchronization, especially the miRNA-mediated cellular behaviors such as such as angiogenesis, proliferation, differentiation, and programmed death ([@ref21]). For example, it has been reported that miR-208b and miR-34a concentrations serve as predictors for left ventricular remodeling after AMI, having a relationship with 6 months of mortality or development of heart failure ([@ref17]). Administration of miR-34a-5p, by binding to STX1A, reportedly suppresses the protective effect of sevoflurane on hypoxia/reoxygenation (H/R)-induced cardiomyocyte damage ([@ref28]). Therapeutic inhibition of members of the miR-34 family attenuates pathological cardiac remodeling and improves heart function ([@ref1]). In addition, an up-regulation of miR-34a-5p was observed in rat cardiomyocytes damaged by doxorubicin (dox)-treatment, and miR-34a-5p enhanced cardiomyocyte cell apoptosis by increasing Bax and caspase-3 expression, and inhibiting Bcl-2 expression ([@ref33]).

CTRP9 expression is known to be decreased in MI. Interestingly, CTRP9 proves to be a target gene of miR-34a-5p. Consistent with results of the current study, adipocyte CTRP9 expression and plasma CTRP9 levels were both decreased after MI ([@ref23]). Besides, miR-31 is considered to promote caspase-3- and caspase-8-dependent apoptosis by negatively regulating the expression of CTRP9 ([@ref22]). Furthermore, following the transplantation of ADSCs into MI mice, down-regulated miR-34a-5p or up-regulated CTRP9 promoted the protective role of ADSCs administration against MI damage. This was reflected by increased LVEF and + dp/dtmax, decreased expression of BNP and ANP in brain, improved LVEDP, lower TUNEL-positive rate, as well as alleviation of cardiac interstitial fibrosis and structural changes of myocardial cells. BNP and LVEF are biomarkers of heart failure, with an established predictive value for cardiac death ([@ref20]). ANP also plays an important role in chronic heart failure since it can delay the progression of the disease ([@ref3]). The present findings indicate that miR-34a-5p may exert important effects on the regulatory mechanism of CTRP9, leading to a protective effect against MI damage.

Another key observation of the current study is that down-regulation of miR-34a-5p can promote ADSC proliferation and migration *in vitro*, while suppressing cardiomyocyte apoptosis in our MI model through CTRP9 up-regulation and activation of the ERK1/2 pathway. Inhibition of miR-34a-5p could alleviate intestinal ischemia/reperfusion-induced injury by promoting the Sirt1-mediated pathway, and inhibiting the accumulation in cardiac epithelium of reactive oxygen species (ROS), while rescuing from apoptosis ([@ref26]). In addition, a prior study showed that an inhibitor of miR-34a-5p could decrease the effect of synthetic steroid hormone treatment on cell proliferation in human ovarian endometrioma ([@ref8]). Knockdown of miR-34a-5p reduced the H/R-induced apoptosis and augmented post-H/R proliferation in steatotic hepatocytes, while up-regulation of miR-34a-5p reversed that trend ([@ref16]). Silencing of miR-34a can significantly increase keratinocyte migration and migration *via* activation of the ERK1/2 pathway ([@ref5]). Additionally, entirely consistent with our findings, CTRP9 has the capacity to promote ADSC proliferation and migration through activation of the ERK1/2-MMP-9 pathway, while increasing cell survival *via* stimulated ERK-NRF2/antioxidative protein expression ([@ref30]). A previous study suggested that CTRP9 decreases myocardial cell apoptosis, and serves as a protection against acute cardiac injury after ischemia-reperfusion through an AMPK-dependent mechanism ([@ref11]). Also, CTRP9 plays an inhibitory role in cell apoptosis, while antagonizing endothelial nitric-oxide synthase (eNOS) expression in cells pre-treated with the PI3K/Akt inhibitor LY294002 ([@ref15]). This result is consistent with a role of ROS in the propagation of damage after AMI.

Conclusion {#sec28}
==========

In conclusion, our key observations in the current study demonstrated that the down-regulation of miR-34a-5p could stimulate the protective effect of ADSC transplantation against MI damage by up-regulating CTRP9 ([Figure 7](#fig7){ref-type="fig"}). Our work provides potential future therapeutic strategies to treat MI, i.e., administration of agents potentiating the beneficial and restorative effects of ADSCs. However, it will be some time before it can be proven that this therapeutic target is applicable for translation to human beings. Additionally, the findings provided in this study are preliminary, calling for more preclinical investigation of this topic.

![A schematic representation of the role of miR-34a-5p in the function of ADSCs in the mouse MI model. miR-34a-5p targets and negatively regulates the expression of CTRP9. Up-regulated CTRP9 could enhance the proliferation and migration of ADSCs by increasing the expression of ERK1, MMP-9, NRF2, MnSOD and HO-1. Therefore, down-regulation of miR-34a-5p plays a promoting role in the protective effect of ADSCs against MI damage by up-regulating CTRP9. miR-34a-5p, microRNA-34a-5p; ADSCs, adipose-derived stem cells; MI, myocardial infarction; CTRP9, C1q/tumor necrosis factor-related protein-9; MMP-9, matrix metalloproteinase-9; NRF2, nuclear factor (erythroid-derived 2)-like 2; HO-1, heme oxygenase-1.](fphys-10-01445-g007){#fig7}
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###### 

Characterization of ADSCs. **(A)** The molecular markers of ADSCs measured by flow cytometry. Dotted lines indicate IgG isotypic negative controls while solid lines indicate CD105-, CD90-, CD45- and CD31-positive animals. **(B)** ADSC morphology observed under an optical microscope (200 ×). **(C)** EGFP fluorescence of ADSCs analyzed under a fluorescence microscope (200 ×). **(D)** Oil red O staining of adipogenic differentiation ability of ADSCs (400 ×). **(E)** Alizarin red staining of osteogenic differentiation ability of ADSCs (200 ×). ADSCs, Adipose-derived stem cells; IgG, Immunoglobulin G; EGFP, Enhanced green fluorescent protein.
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